About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT02812589

Diffusion Tensor Breast MRI (DTI)

The breast MRI is used in the preoperative scenario to evaluate the extension of a newly diagnosed breast cancer and to screen the contralateral breast. The scan consists of a series of images taken a...

Lead sponsor: University Health Network, Toronto•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Health Network, Toronto

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•Female of any race, ethnicity and lifetime risk.
•Eighteen years or older.
•Known recent diagnosis of a breast cancer and normal clinical breast exam of the contralateral side.
•Self-detected lump suspicious for breast cancer that it has not been biopsied yet.

Exclusion Criteria

•Inability to understand the consent form
•Pregnant or nursing
•Currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor for adjuvant therapy or chemoprevention
•Physically unable to lie down on her belly for at least 10 minutes.
•Have had benign needle biopsy of the breast performed within 3 months, or breast surgery within 1 year prior to MRI exam.

Related studies

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

NCT07586215 · Breast Cancer Metastatic

RC48-ADC in HER2-low Advanced Breast Cancer

NCT05831878 · Advanced Breast Cancer

RECRUITINGPhase 2

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

NCT07368998 · Breast Cancer

RECRUITINGPhase 4

A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients

NCT07578064 · Breast Cancer, Bone Marrow Suppression

RECRUITINGPhase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 13, 2021Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment267

Start dateApr 2016

Last updatedApr 13, 2021

Condition

Locations shown

Princess Margaret Cancer Centre, University Health Network, 610 University Ave.

Toronto, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions